Loading news...
C4 Therapeutics, Inc. (CCCC) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
C4 Therapeutics delivered strong 4Q25 results, with revenue up 111.5% YoY and operating expenses tightly controlled. CCCC's lead asset, cemsidomide, advanced into a Phase 2 registrational trial for relapsed/refractory multiple myeloma, targeting a large, growing TAM. Cash position strengthened to $297.1M, extending operational runway through 2028 and supporting continued pipeline investment.
WATERTOWN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase 85,480 shares of the Company's common stock to one new employee (the “Inducement Grant”), with the grant made on March 9, 2026 (the “Grant Date”). The Inducement Grant was granted as a material inducement to this individual entering into employment with C4T in accordance with Nasdaq Listing Rule 5635(c)(4).
C4 Therapeutics (NASDAQ: CCCC) used a presentation at TD Cowen's 46th Annual Healthcare Conference to outline its near- and mid-term clinical plans, emphasizing its lead multiple myeloma program cemsidomide and a development strategy aimed at potential accelerated approval pathways. Focus on targeted protein degradation and a lead myeloma program Chief Executive Officer Andrew Hirsch described C4
Does C4 Therapeutics, Inc. (CCCC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Cemsidomide Advancing into Later-stage Development with Potential for Accelerated Approval; First Patient Dosed in the Phase 2 MOMENTUM Trial for Multiple Myeloma in the Fourth Line or Later Phase 1b Trial of Cemsidomide in Combination with Elranatamab on Track to Initiate in Q2 2026 to Support Use in Earlier Lines of Multiple Myeloma Therapy Second Degrader Designed and Delivered to Biogen Entered Clinical Development for Autoimmune Diseases Strong Balance Sheet Provides Runway to the End of 2028; Cash, Cash Equivalents and Marketable Securities of $297.1 million as of December 31, 2025 WATERTOWN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today reported financial results for the year ended December 31, 2025, as well as business updates.
C4 Therapeutics, Inc. (NASDAQ: CCCC - Get Free Report) has received an average rating of "Moderate Buy" from the eight ratings firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have assigned a buy recommendation to the
WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will participate in two upcoming March conferences.
Enrollment for Phase 2 MOMENTUM Trial Expected to Be Completed in Q1 2027 Phase 1b Trial of Cemsidomide in Combination with Elranatamab on Track to Initiate in Q2 2026 WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the first patient has been dosed in the Phase 2 MOMENTUM trial evaluating cemsidomide in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma (RRMM).
WATERTOWN, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase 162,880 shares of the Company's common stock to one new employee (the “Inducement Grant”), with the grant made on February 9, 2026 (the “Grant Date”). The Inducement Grant was granted as a material inducement to this individual entering into employment with C4T in accordance with Nasdaq Listing Rule 5635(c)(4).
WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 taking place from February 11 – 12, 2026 in New York, NY.
WATERTOWN, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase 85,480 shares of the Company's common stock to one new employee (the “Inducement Grant”), with the grant made on January 26, 2026 (the “Grant Date”). The Inducement Grant was granted as a material inducement to this individual entering into employment with C4T in accordance with Nasdaq Listing Rule 5635(c)(4).
C4 Therapeutics, Inc. (NASDAQ: CCCC - Get Free Report) insider Leonard Reyno sold 10,000 shares of the stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $2.22, for a total value of $22,200.00. Following the transaction, the insider directly owned 156,382 shares in the company, valued at approximately
Cemsidomide Phase 2 MOMENTUM Trial On Track to Initiate in Q1 2026; Recommended Phase 2 Dose is 100 µg Cemsidomide Phase 1b Trial in Combination With Elranatamab On Track to Initiate in Q2 2026 Internal Discovery Strategy Progressing Efforts Focused on Inflammation, Neuro-inflammation and Neuro-degenerative Diseases With Novel Targets in Clinically Validated Pathways Cash Runway to End of 2028 Provides Funding Through Key Value Inflection Points WATERTOWN, Mass., Jan. 14, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today outlined milestones through 2028 and highlighted recent achievements.
C4 Therapeutics, Inc. (NASDAQ: CCCC - Get Free Report) saw some unusual options trading activity on Wednesday. Stock traders purchased 5,066 call options on the company. This represents an increase of 390% compared to the typical volume of 1,033 call options. C4 Therapeutics Price Performance Shares of CCCC opened at $2.05 on Thursday. The company has
C4 Therapeutics reported a Q3 GAAP EPS loss of –$0.44, missing estimates, but revenue of $11.23M beat expectations by $4.95M. CCCC's lead asset, cemsidomide, showed promising Phase 1 results in multiple myeloma and is advancing to pivotal Phase 2 and combination trials in 2026. Despite a net loss and heavy R&D spending, the company boasts a strong cash position and trades at a discount to sector peers, with limited pipeline premium.
WATERTOWN, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that C4T management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference taking place from December 2 - 4, 2025 in Coral Gables, Florida.
Esperion Therapeutics, Inc. and C4 Therapeutics, Inc. were among the top contributors to performance. SiTime Corp. was also a top contributor. The company provides silicon timing chips for a wide range of electronics. The greatest detractor from Fund performance for the quarter was Monday.com Ltd.
C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to a loss of $0.35 per share a year ago.
Completed Equity Offering Resulted in $125 Million in Gross Proceeds, Extending Runway to End of 2028, Beyond Key Value Inflection Points; Potential to Earn up to an Additional $225 Million in Proceeds Cemsidomide Phase 1 Multiple Myeloma Data Support Potential Best-in-Class Profile With a 53% Overall Response Rate at the Highest Dose Level (100 µg) and Differentiated Safety and Tolerability Profile Entered Into Clinical Trial Collaboration and Supply Agreement With Pfizer to Evaluate Cemsidomide in Combination With Elranatamab On Track to Initiate Next Phase of Cemsidomide Multiple Myeloma Development Including Registrational Phase 2 MOMENTUM Trial in Combination with Dexamethasone in Q1 2026 and Phase 1b Trial in Combination with Elranatamab in Q2 2026 WATERTOWN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today reported financial results for the third quarter ended September 30, 2025, as well as business updates.